Clinical Trial Search

Primary: Incidence and Severity of Treatment-emergent Adverse Events (TEAEs) — 33; 33; 31; 32 Participants

Primary: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib — 389.1; 398.3; 378.0; 387.8 nanogram*hour per…

Primary: Maximum Tolerated Dose (MTD) Recommended Dose of Pembrolizumab in Combination With Lead in Pembrolizumab and Afatinib Dimaleate — 40 mg

Primary: Percentage of Participants Who Experienced Dose-Limiting Toxicity (DLT) — 16.7; 0.0; 0.0; 27.3 Percetange of Participants

Primary: Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) Following Single Dose of GSK3923868 — 1; 2; 1; 0 Participants

Primary: Part 1: Number of Participants Who Experienced Dose-limiting Toxicity (DLT) — 0; 1; 1 Participants

Primary: Serum Concentrations of Estriol (E3) — 0; 0.91; 3.83; 1.58 pg/ml

Primary: To Determine the Steady State Concentration (Css) for Estradiol — 14.4; 29.7; 33.8 pg/mL

Primary: Number ot Participants With Treatment Emergent Adverse Events — 2; 2; 2; 1 participants

Primary: Phase 1a (Arm A): Number of Participants Who Experienced at Least One Dose-limiting Toxicity (DLT) According to National Cancer Institute-Common Terminology Criteria for…

Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tirzepatide — 647; 524 nanograms per milliliter (ng/mL)

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in PART-1: SAD — 2; 1; 1; 0 Participants

Primary: Number of Participants With Treatment Related Adverse Events — 1 Participants

Primary: Number of Adverse Events Common Terminology Criteria for Adverse Events Version 4.0 — 0; 1; 8; 0 Participants

Primary: Recruitment — 24 Participants